Clinical trial updates alert professionals to new advancements in aesthetic dermatology. A major study expands the scope of Ellacor® Micro-Coring Technology® to include patients receiving glucagon-like peptide-1 receptor agonists (GLP-1 agonists).
On November 7, 2025, an announcement confirmed the recruitment phase for a groundbreaking trial sponsored by Cytrellis Biosystems, Inc., testing Ellacor® on Fitzpatrick skin types I–VI. Professionals in dermatology, clinical research, and regulatory affairs will want to follow developments closely as technology intersects with metabolic therapy patient populations.
- What changed?
- How does Ellacor® technology work?
- Who is impacted?
- Detailed study conditions
- FAQ
- Conclusion
- Disclaimer
- Full announcement link
What changed?
The trial introduces an innovative intersection between aesthetic dermatology and special population studies. It includes patients receiving GLP-1 receptor agonists—typically prescribed for conditions like type 2 diabetes and obesity. The research extends to Fitzpatrick skin types I–VI, ensuring inclusivity across pigmentation profiles.
An essential step in personalized medicine, this study seeks to understand the effects of Ellacor®, a device designed for micro-coring dermal tissue, among a diverse population. GLP-1 agonist therapies could potentially influence skin laxity outcomes.
How does Ellacor® technology work?
Ellacor® Micro-Coring Technology® differentiates itself by strategic dermal extraction rather than energy-based or surgical methods. The device removes micro-portions of skin tissue without incisions or thermal injury. The aim is enhanced skin tightening and rejuvenation.
FDA clearance already supports its aesthetic application for tissue restructuring. The integration with metabolic pharmaceutical contexts such as GLP-1 agonists adds exploratory dimensions to its efficacy. Patients undergoing treatment could exhibit distinct dermal responses.
Who is impacted?
Medical and regulatory teams monitoring cross-functional technologies should note this development. Dermatologists may gain insights into treatments for more diverse populations, including individuals on metabolic interventions.
Patients receiving GLP-1 receptor agonists often experience weight loss, which in some may elevate skin laxity concerns. This trial aims to assess micro-coring against such specific challenges, paving the way for targeted applications.
Detailed study conditions
Cytrellis Biosystems, Inc., sponsors the initiative, classified under ClinicalTrials.gov parameters as an interventional trial recruiting participants actively.
Participants will be assessed for skin laxity improvement, gene expression interactions, and device-based outcomes. Conditions include Fitzpatrick classification (I–VI) and concurrent GLP-1 agonist application.
The study also emphasizes measurable safety benchmarks aligned with regulatory protocols to assure patient welfare.
FAQ
- What are Fitzpatrick skin types?
Fitzpatrick skin types classify dermatological pigmentation ranges from type I (fair) to type VI (deeply pigmented). - What are GLP-1 receptor agonists?
GLP-1 receptor agonists are medications used to manage type 2 diabetes and aid in weight management by regulating glucose metabolism. - Is Ellacor® FDA-cleared?
Yes, Ellacor® Micro-Coring Technology® holds FDA clearance for aesthetic skin tightening applications but integrates novel patient fields in its current trial. - Who qualifies for this trial?
Patients categorized under Fitzpatrick classifications I–VI and those prescribed GLP-1 receptor agonists may qualify. - Will results apply to all skin tones?
Yes. The trial spans Fitzpatrick types I–VI, aiming for efficacy across diverse pigmentation groups.
Conclusion
This trial signals a shift in aesthetic research, pairing device functionality with pharmaceutical patient profiles. Regulatory teams, researchers, and physicians should evaluate outcomes for wide-reaching implications on skin laxity management.
Professionals seeking innovative skin treatments or clinical data should consider monitoring updates to this study closely.
Disclaimer
This post is informational only and does not constitute legal or medical advice. Always refer to clinicaltrial.gov or regulatory authorities for current guidelines.
Full announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07224880?term=medical+device